drugset / Trial / NCT05667220
Sitagliptin in Combination With Beidougen Capsule for Type 2 Diabetes
Non-randomizedParallel-groupOpen-labelBasic science
Summary
The study was an interventional non-randomized controlled study and was divided into a Sitagliptin monotherapy (100 mg Qd) group and a Sitagliptin (100mg Qd)+Beidougen capsule (60mg Tid) combination treatment group for one week.
Timeline
- Start
- 2022-12-01
- Primary completion
- 2023-10-31
- Completion
- 2023-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BeiDouGen | Unknown | 60 mg | Oral |
| Comparator | Sitagliptin | Small molecule | 100 mg | Oral |